Suman Tandon, MD, a representative of the American Society of Nuclear Cardiology, explains her organization's concerns about artificial intelligence being used to automatically deny prior authorizations and prevent patients from accessing care.
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
After being ordered to pay $442 million in damages—a ruling the company has said it may appeal—Johnson & Johnson MedTech is now facing the possibility of a permanent injunction that could impact certain business practices. A hearing is scheduled for July.
The group highlighted the proven effectiveness of these drugs, especially semaglutide and tirzepatide, while noting that eligibility, affordability and availability will still play key roles in any treatment decisions.
An example of structural valve deterioration that shows a biological prosthetic heart valve in the aortic position. There is severe calcification and thickening of the leaflets compatible with structural valve deterioration. 3D VRT (A) and in-plane reconstructions (B). Images and caption courtesy of Budde et al. and RSNA.
RSNA and several other industry societies have shared a new expert consensus document on the significant value of cardiac CT. Echo remains an effective first-line imaging option, the groups wrote, but CT can make a big impact as well.
After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained.
American Medical Association President Bruce Scott, MD, explains the growing issues with insurance prior authorization impacting patient care and what the AMA is doing about it.